{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:47:06Z","timestamp":1759970826857,"version":"build-2065373602"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFF1201300","2021YFF1201300","2021YFF1201300","2021YFF1201300","2021YFF1201300","2021YFF1201300"],"award-info":[{"award-number":["2021YFF1201300","2021YFF1201300","2021YFF1201300","2021YFF1201300","2021YFF1201300","2021YFF1201300"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2022-I2M-2-001","2022-I2M-2-001","2022-I2M-2-001","2022-I2M-2-001","2022-I2M-2-001","2022-I2M-2-001"],"award-info":[{"award-number":["2022-I2M-2-001","2022-I2M-2-001","2022-I2M-2-001","2022-I2M-2-001","2022-I2M-2-001","2022-I2M-2-001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"DOI":"10.1186\/s12859-025-06252-8","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:01:34Z","timestamp":1759917694000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MyClone: rapid and precise reconstruction of clonal population structures for tumors"],"prefix":"10.1186","volume":"26","author":[{"given":"Qihan","family":"Guo","sequence":"first","affiliation":[]},{"given":"Dan","family":"Lv","sequence":"additional","affiliation":[]},{"given":"Bo","family":"Lan","sequence":"additional","affiliation":[]},{"given":"Haili","family":"Qian","sequence":"additional","affiliation":[]},{"given":"Fei","family":"Ma","sequence":"additional","affiliation":[]},{"given":"Ting","family":"Chen","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"issue":"12","key":"6252_CR1","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/nrc2013","volume":"6","author":"LMF Merlo","year":"2006","unstructured":"Merlo LMF, Pepper JW, Reid BJ, et al. Cancer as an evolutionary and ecological process. Nat Rev Cancer. 2006;6(12):924\u201335.","journal-title":"Nat Rev Cancer"},{"key":"6252_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1752-4571.2008.00063.x","volume":"2","author":"JW Pepper","year":"2009","unstructured":"Pepper JW, Scott Findlay C, Kassen R. Cancer research meets evolutionary biology. Evol Appl. 2009;2:62\u201370.","journal-title":"Evol Appl"},{"issue":"4260","key":"6252_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1126\/science.959840","volume":"194","author":"PC Nowell","year":"1976","unstructured":"Nowell PC. The clonal evolution of tumor cell populations: acquired genetic lability permits stepwise selection of variant sublines and underlies tumor progression. Science. 1976;194(4260):23\u20138.","journal-title":"Science"},{"issue":"9","key":"6252_CR4","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra1204892","volume":"368","author":"S Aparicio","year":"2013","unstructured":"Aparicio S, Caldas C. The implications of clonal genome evolution for cancer medicine. N Engl J Med. 2013;368(9):842\u201351.","journal-title":"N Engl J Med"},{"issue":"11","key":"6252_CR5","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1158\/1940-6207.CAPR-10-0108","volume":"3","author":"LMF Merlo","year":"2010","unstructured":"Merlo LMF, Shah NA, Li X, et al. A comprehensive survey of clonal diversity measures in Barrett\u2019s esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev Res. 2010;3(11):1388\u201397.","journal-title":"Cancer Prev Res"},{"issue":"5","key":"6252_CR6","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","volume":"120","author":"JJ Keats","year":"2012","unstructured":"Keats JJ, Chesi M, Egan JB, et al. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012;120(5):1067\u201376.","journal-title":"Blood"},{"issue":"2","key":"6252_CR7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/path.4278","volume":"232","author":"BG Blair","year":"2014","unstructured":"Blair BG, Bardelli A, Park BH. Somatic alterations as the basis for resistance to targeted therapies. J Pathol. 2014;232(2):244\u201354.","journal-title":"J Pathol"},{"issue":"2","key":"6252_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15(2):81\u201394.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"6252_CR9","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.molonc.2014.06.005","volume":"8","author":"RA Burrell","year":"2014","unstructured":"Burrell RA, Swanton C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol. 2014;8(6):1095\u2013111.","journal-title":"Mol Oncol"},{"issue":"10","key":"6252_CR10","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan C, Van Schaeybroeck S, Longley DB, et al. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714\u201326.","journal-title":"Nat Rev Cancer"},{"key":"6252_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/gb-2010-11-8-r82","volume":"11","author":"SJM Jones","year":"2010","unstructured":"Jones SJM, Laskin J, Li YY, et al. Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biol. 2010;11:1\u201312.","journal-title":"Genome Biol"},{"issue":"7467","key":"6252_CR12","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nature12627","volume":"501","author":"PL Bedard","year":"2013","unstructured":"Bedard PL, Hansen AR, Ratain MJ, et al. Tumour heterogeneity in the clinic. Nature. 2013;501(7467):355\u201364.","journal-title":"Nature"},{"issue":"1","key":"6252_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57\u201370.","journal-title":"Cell"},{"issue":"5","key":"6252_CR14","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"key":"6252_CR15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ebiom.2019.04.003","volume":"43","author":"Y Wang","year":"2019","unstructured":"Wang Y, Zhao C, Chang L, et al. Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer. EBioMedicine. 2019;43:261\u20139.","journal-title":"EBioMedicine"},{"issue":"22","key":"6252_CR16","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","volume":"376","author":"M Jamal-Hanjani","year":"2017","unstructured":"Jamal-Hanjani M, Wilson GA, McGranahan N, et al. Tracking the evolution of non\u2013small-cell lung cancer. N Engl J Med. 2017;376(22):2109\u201321.","journal-title":"N Engl J Med"},{"issue":"7341","key":"6252_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nature09807","volume":"472","author":"N Navin","year":"2011","unstructured":"Navin N, Kendall J, Troge J, et al. Tumour evolution inferred by single-cell sequencing. Nature. 2011;472(7341):90\u20134.","journal-title":"Nature"},{"issue":"5","key":"6252_CR18","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.cell.2012.02.025","volume":"148","author":"X Xu","year":"2012","unstructured":"Xu X, Hou Y, Yin X, et al. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell. 2012;148(5):886\u201395.","journal-title":"Cell"},{"issue":"7","key":"6252_CR19","doi-asserted-by":"publisher","first-page":"e1004462","DOI":"10.1371\/journal.pgen.1004462","volume":"10","author":"AE Hughes","year":"2014","unstructured":"Hughes AE, O, Magrini V, Demeter R, et al. Clonal architecture of secondary acute myeloid leukemia defined by single-cell sequencing. PLoS Genet. 2014;10(7):e1004462.","journal-title":"PLoS Genet"},{"issue":"5","key":"6252_CR20","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.cell.2012.02.028","volume":"148","author":"Y Hou","year":"2012","unstructured":"Hou Y, Song L, Zhu P, et al. Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell. 2012;148(5):873\u201385.","journal-title":"Cell"},{"issue":"8","key":"6252_CR21","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026625","volume":"7","author":"SC Dentro","year":"2017","unstructured":"Dentro SC, Wedge DC, Van Loo P. Principles of reconstructing the subclonal architecture of cancers. Cold Spring Harb Perspect Med. 2017;7(8):a026625.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"6252_CR22","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/sysbio\/syu081","volume":"64","author":"N Beerenwinkel","year":"2015","unstructured":"Beerenwinkel N, Schwarz RF, Gerstung M, et al. Cancer evolution: mathematical models and computational inference. Syst Biol. 2015;64(1):e1\u201325.","journal-title":"Syst Biol"},{"issue":"2","key":"6252_CR23","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41592-020-01013-2","volume":"18","author":"M Tarabichi","year":"2021","unstructured":"Tarabichi M, Salcedo A, Deshwar AG, et al. A practical guide to cancer subclonal reconstruction from DNA sequencing. Nat Methods. 2021;18(2):144\u201355.","journal-title":"Nat Methods"},{"key":"6252_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12859-020-03919-2","volume":"21","author":"S Gillis","year":"2020","unstructured":"Gillis S, Roth A. Pyclone-VI: scalable inference of clonal population structures using whole genome data. BMC Bioinformatics. 2020;21:1\u201316.","journal-title":"BMC Bioinformatics"},{"issue":"8","key":"6252_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1003665","volume":"10","author":"CA Miller","year":"2014","unstructured":"Miller CA, White BS, Dees ND, et al. SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput Biol. 2014;10(8):e1003665.","journal-title":"PLoS Comput Biol"},{"key":"6252_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-015-0602-8","volume":"16","author":"AG Deshwar","year":"2015","unstructured":"Deshwar AG, Vembu S, Yung CK, et al. Phylowgs: reconstructing subclonal composition and evolution from whole-genome sequencing of tumors. Genome Biol. 2015;16:1\u201320.","journal-title":"Genome Biol"},{"issue":"9","key":"6252_CR27","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41588-020-0675-5","volume":"52","author":"G Caravagna","year":"2020","unstructured":"Caravagna G, Heide T, Williams MJ, et al. Subclonal reconstruction of tumors by using machine learning and population genetics. Nat Genet. 2020;52(9):898\u2013907.","journal-title":"Nat Genet"},{"issue":"4","key":"6252_CR28","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nmeth.2883","volume":"11","author":"A Roth","year":"2014","unstructured":"Roth A, Khattra J, Yap D, et al. Pyclone: statistical inference of clonal population structure in cancer. Nat Methods. 2014;11(4):396\u20138.","journal-title":"Nat Methods"},{"key":"6252_CR29","doi-asserted-by":"crossref","unstructured":"Sengupta S, Wang J, Lee J et al. Bayclone: Bayesian nonparametric inference of tumor subclones using NGS data. Pacific symposium on biocomputing co-chairs. 2014: 467\u2013478.","DOI":"10.1142\/9789814644730_0044"},{"key":"6252_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2105-15-35","volume":"15","author":"W Jiao","year":"2014","unstructured":"Jiao W, Vembu S, Deshwar AG, et al. Inferring clonal evolution of tumors from single nucleotide somatic mutations. BMC Bioinformatics. 2014;15:1\u201316.","journal-title":"BMC Bioinformatics"},{"issue":"5","key":"6252_CR31","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.cell.2012.04.023","volume":"149","author":"S Nik-Zainal","year":"2012","unstructured":"Nik-Zainal S, Van Loo P, Wedge DC, et al. The life history of 21 breast cancers. Cell. 2012;149(5):994\u20131007.","journal-title":"Cell"},{"issue":"1","key":"6252_CR32","doi-asserted-by":"publisher","first-page":"4469","DOI":"10.1038\/s41467-020-18169-2","volume":"11","author":"Y Xiao","year":"2020","unstructured":"Xiao Y, Wang X, Zhang H, et al. Fastclone is a probabilistic tool for deconvoluting tumor heterogeneity in bulk-sequencing samples. Nat Commun. 2020;11(1):4469.","journal-title":"Nat Commun"},{"issue":"4","key":"6252_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2022.101706","volume":"3","author":"E Kulman","year":"2022","unstructured":"Kulman E, Wintersinger J, Morris Q. Reconstructing cancer phylogenies using pairtree, a clone tree reconstruction algorithm. STAR Protoc. 2022;3(4):101706.","journal-title":"STAR Protoc"},{"issue":"1","key":"6252_CR34","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41596-023-00913-9","volume":"19","author":"K Grigoriadis","year":"2024","unstructured":"Grigoriadis K, Huebner A, Bunkum A, et al. Conipher: a computational framework for scalable phylogenetic reconstruction with error correction. Nat Protoc. 2024;19(1):159\u201383.","journal-title":"Nat Protoc"},{"issue":"10","key":"6252_CR35","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.cels.2021.07.006","volume":"12","author":"G Satas","year":"2021","unstructured":"Satas G, Zaccaria S, El-Kebir M, et al. DeCiFering the elusive cancer cell fraction in tumor heterogeneity and evolution. Cell Syst. 2021;12(10):1004\u201318. e10.","journal-title":"Cell Syst"},{"issue":"6","key":"6252_CR36","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1038\/nprot.2018.033","volume":"13","author":"Y Cun","year":"2018","unstructured":"Cun Y, Yang TP, Achter V, et al. Copy-number analysis and inference of subclonal populations in cancer genomes using sclust. Nat Protoc. 2018;13(6):1488\u2013501.","journal-title":"Nat Protoc"},{"issue":"6","key":"6252_CR37","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.cels.2019.05.010","volume":"8","author":"MA Myers","year":"2019","unstructured":"Myers MA, Satas G, Raphael BJ. CALDER: inferring phylogenetic trees from longitudinal tumor samples. Cell Syst. 2019;8(6):514\u201322. e5.","journal-title":"Cell Syst"},{"issue":"8","key":"6252_CR38","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/j.cell.2021.03.009","volume":"184","author":"SC Dentro","year":"2021","unstructured":"Dentro SC, Leshchiner I, Haase K, et al. Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. Cell. 2021;184(8):2239\u201354. e39.","journal-title":"Cell"},{"issue":"7921","key":"6252_CR39","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41586-022-04975-9","volume":"608","author":"C Herberts","year":"2022","unstructured":"Herberts C, Annala M, Sipola J, et al. Deep whole-genome ctdna chronology of treatment-resistant prostate cancer. Nature. 2022;608(7921):199\u2013208.","journal-title":"Nature"},{"key":"6252_CR40","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s10147-018-1373-5","volume":"24","author":"J Tsuchida","year":"2019","unstructured":"Tsuchida J, Rothman J, McDonald KA, et al. Clinical target sequencing for precision medicine of breast cancer. Int J Clin Oncol. 2019;24:131\u201340.","journal-title":"Int J Clin Oncol"},{"key":"6252_CR41","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.csbj.2019.10.004","volume":"17","author":"F Bewicke-Copley","year":"2019","unstructured":"Bewicke-Copley F, Kumar EA, Palladino G, et al. Applications and analysis of targeted genomic sequencing in cancer studies. Comput Struct Biotechnol J. 2019;17:1348\u201359.","journal-title":"Comput Struct Biotechnol J"},{"issue":"5","key":"6252_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064271","volume":"8","author":"SW Han","year":"2013","unstructured":"Han SW, Kim HP, Shin JY, et al. Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing. PLoS One. 2013;8(5):e64271.","journal-title":"PLoS One"},{"issue":"5","key":"6252_CR43","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1002\/ijc.32536","volume":"146","author":"F Ma","year":"2020","unstructured":"Ma F, Guan Y, Yi Z, et al. Assessing tumor heterogeneity using ctdna to predict and monitor therapeutic response in metastatic breast cancer. Int J Cancer. 2020;146(5):1359\u201368.","journal-title":"Int J Cancer"},{"key":"6252_CR44","unstructured":"Rosenberg A, Hirschberg J. V-measure: A conditional entropy-based external cluster evaluation measure. Proceedings of the 2007 joint conference on empirical methods in natural language processing and computational natural language learning (EMNLP-CoNLL). 2007: 410\u2013420."},{"issue":"7957","key":"6252_CR45","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41586-023-05783-5","volume":"616","author":"AM Frankell","year":"2023","unstructured":"Frankell AM, Dietzen M, Al Bakir M, et al. The evolution of lung cancer and impact of subclonal selection in tracerx. Nature. 2023;616(7957):525\u201333.","journal-title":"Nature"},{"issue":"7382","key":"6252_CR46","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature10738","volume":"481","author":"L Ding","year":"2012","unstructured":"Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481(7382):506\u201310.","journal-title":"Nature"},{"issue":"7291","key":"6252_CR47","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/nature08989","volume":"464","author":"LI Ding","year":"2010","unstructured":"Ding LI, Ellis MJ, Li S, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature. 2010;464(7291):999\u20131005.","journal-title":"Nature"},{"issue":"11","key":"6252_CR48","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","volume":"361","author":"ER Mardis","year":"2009","unstructured":"Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361(11):1058\u201366.","journal-title":"N Engl J Med"},{"issue":"7539","key":"6252_CR49","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/nature13952","volume":"518","author":"P Eirew","year":"2015","unstructured":"Eirew P, Steif A, Khattra J, et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature. 2015;518(7539):422\u20136.","journal-title":"Nature"},{"issue":"7","key":"6252_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0134463","volume":"10","author":"V Vymetalkova","year":"2015","unstructured":"Vymetalkova V, Soucek P, Kunicka T, et al. Genotype and haplotype analyses of TP53 gene in breast cancer patients: association with risk and clinical outcomes. PLoS One. 2015;10(7):e0134463.","journal-title":"PLoS One"},{"issue":"4","key":"6252_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019249","volume":"6","author":"R Chrisanthar","year":"2011","unstructured":"Chrisanthar R, Knappskog S, L\u00f8kkevik E, et al. Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel. PLoS One. 2011;6(4):e19249.","journal-title":"PLoS One"},{"issue":"3","key":"6252_CR52","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/jnci\/djaa087","volume":"113","author":"B O\u2019Leary","year":"2021","unstructured":"O\u2019Leary B, Cutts RJ, Huang X, et al. Circulating tumor DNA markers for early progression on fulvestrant with or without palbociclib in ER\u2009+\u2009advanced breast cancer. JNCI J Natl Cancer Inst. 2021;113(3):309\u201317.","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"1","key":"6252_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clbc.2013.10.014","volume":"14","author":"CL Vogel","year":"2014","unstructured":"Vogel CL, Johnston MA, Capers C, et al. Toremifene for breast cancer: a review of 20 years of data. Clin Breast Cancer. 2014;14(1):1\u20139.","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"6252_CR54","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41416-021-01564-x","volume":"126","author":"SK Herzog","year":"2022","unstructured":"Herzog SK, Fuqua SAW. ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges. Br J Cancer. 2022;126(2):174\u201386.","journal-title":"Br J Cancer"},{"issue":"3","key":"6252_CR55","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-055821","volume":"12","author":"F Berger","year":"2022","unstructured":"Berger F, Marce M, Delaloge S, et al. Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of Palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1. BMJ Open. 2022;12(3):e055821.","journal-title":"BMJ Open"},{"key":"6252_CR56","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.breast.2020.04.004","volume":"52","author":"Z Yi","year":"2020","unstructured":"Yi Z, Liu B, Sun X, et al. Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers. Breast. 2020;52:17\u201322.","journal-title":"Breast"},{"issue":"7381","key":"6252_CR57","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/nature10762","volume":"481","author":"M Greaves","year":"2012","unstructured":"Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481(7381):306\u201313.","journal-title":"Nature"},{"issue":"27","key":"6252_CR58","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1200\/JCO.2016.69.6179","volume":"35","author":"F Ma","year":"2017","unstructured":"Ma F, Li Q, Chen S, et al. Phase I study and biomarker analysis of pyrotinib, a novel irreversible pan-ERBB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2\u2013positive metastatic breast cancer. J Clin Oncol. 2017;35(27):3105\u201312.","journal-title":"J Clin Oncol"},{"issue":"1","key":"6252_CR59","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40364-023-00453-0","volume":"11","author":"X Guan","year":"2023","unstructured":"Guan X, Ma F, Li Q, et al. Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies. Biomark Res. 2023;11(1):21.","journal-title":"Biomark Res"},{"issue":"16","key":"6252_CR60","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1007\/s40265-020-01394-w","volume":"80","author":"SE Nunnery","year":"2020","unstructured":"Nunnery SE, Mayer IA. Targeting the PI3K\/AKT\/mTOR pathway in hormone-positive breast cancer. Drugs. 2020;80(16):1685\u201397.","journal-title":"Drugs"},{"issue":"9","key":"6252_CR61","first-page":"6055","volume":"11","author":"D Huang","year":"2019","unstructured":"Huang D, Tang L, Yang F, et al. PIK3CA mutations contribute to fulvestrant resistance in ER-positive breast cancer. Am J Translational Res. 2019;11(9):6055.","journal-title":"Am J Translational Res"},{"issue":"3","key":"6252_CR62","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3390\/cells12030493","volume":"12","author":"XM Pei","year":"2023","unstructured":"Pei XM, Yeung MHY, Wong ANN, et al. Targeted sequencing approach and its clinical applications for the molecular diagnosis of human diseases. Cells. 2023;12(3):493.","journal-title":"Cells"},{"issue":"49","key":"6252_CR63","doi-asserted-by":"publisher","first-page":"5943","DOI":"10.1038\/onc.2015.90","volume":"34","author":"H Nakagawa","year":"2015","unstructured":"Nakagawa H, Wardell CP, Furuta M, et al. Cancer whole-genome sequencing: present and future. Oncogene. 2015;34(49):5943\u201350.","journal-title":"Oncogene"},{"issue":"5","key":"6252_CR64","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","volume":"18","author":"M Ignatiadis","year":"2021","unstructured":"Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic\u2014implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18(5):297\u2013312.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"6252_CR65","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1158\/0008-5472.CAN-21-1718","volume":"82","author":"JC Stadler","year":"2022","unstructured":"Stadler JC, Belloum Y, Deitert B, et al. Current and future clinical applications of ctdna in immuno-oncology. Cancer Res. 2022;82(3):349\u201358.","journal-title":"Cancer Res"},{"issue":"4","key":"6252_CR66","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"JCM Wan","year":"2017","unstructured":"Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223\u201338.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"6252_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100060","volume":"6","author":"L De Mattos-Arruda","year":"2021","unstructured":"De Mattos-Arruda L, Siravegna G. How to use liquid biopsies to treat patients with cancer. ESMO Open. 2021;6(2):100060.","journal-title":"ESMO Open"},{"issue":"1","key":"6252_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00895-x","volume":"13","author":"ZT Weber","year":"2021","unstructured":"Weber ZT, Collier KA, Tallman D, et al. Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer. Genome Med. 2021;13(1):89.","journal-title":"Genome Med"},{"issue":"7655","key":"6252_CR69","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature22364","volume":"545","author":"C Abbosh","year":"2017","unstructured":"Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctdna analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446\u201351.","journal-title":"Nature"},{"issue":"1","key":"6252_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00662-9","volume":"6","author":"Z Yi","year":"2021","unstructured":"Yi Z, Ma F, Rong G, et al. The molecular tumor burden index as a response evaluation criterion in breast cancer. Signal Transduct Target Ther. 2021;6(1):251.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"6252_CR71","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.gpb.2021.08.001","volume":"19","author":"T Chen","year":"2021","unstructured":"Chen T, Chen X, Zhang S, et al. The genome sequence archive family: toward explosive data growth and diverse data types. Genomics Proteomics Bioinformatics. 2021;19(4):578\u201383.","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"D1","key":"6252_CR72","doi-asserted-by":"publisher","first-page":"D27","DOI":"10.1093\/nar\/gkab951","volume":"50","author":"Database resources of the national genomics data center","year":"2022","unstructured":"Database resources of the national genomics data center. China National center for bioinformation in 2022. Nucleic Acids Res. 2022;50(D1):D27\u201338.","journal-title":"Nucleic Acids Res"}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-025-06252-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12859-025-06252-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-025-06252-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T11:07:03Z","timestamp":1759921623000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/s12859-025-06252-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6252"],"URL":"https:\/\/doi.org\/10.1186\/s12859-025-06252-8","relation":{},"ISSN":["1471-2105"],"issn-type":[{"type":"electronic","value":"1471-2105"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"31 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study adhered to the Helsinki Declaration and was approved by the Institutional Review Board of the National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital. Informed consent to participate in the study was obtained from all participants prior to their inclusion in the research. All patients enrolled in this study voluntarily participated in biomarker research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"242"}}